Iphigenie Korakis
14 Papers
Iphigenie Korakis is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers
Aurélien Voissiere,Carlos Gomez-Roca,Sylvie Chabaud,Céline Rodriguez,Axelle Nkodia,Justine Berthet,L. Montané,Anne-Sophie Bidaux,Isabelle Treilleux,Lauriane Eberst,C. Terret,Iphigenie Korakis,Gwenaelle Garin,David Pérol,Jean-Pierre Delord,Christophe Caux,Bertrand Dubois,Christine Ménétrier-Caux,Nathalie Bendriss-Vermare,Philippe A. Cassier +19 more
TL;DR: The authors found that pexidartinib affected the development of dendritic cells (DCs), which explained the limited efficacy of pexidartinib, and suggested that inhibition of FLT3 should be considered when combining TKIs with immune checkpoint inhibitors.
14
Interim safety and efficacy results from AURELIO-03: A phase 1 dose escalation study of the IL-2/IL-15 receptor βγ superagonist SOT101 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
M. Elena Garralda,Aung Naing,Vladimir Galvao,Patricia LoRusso,Peter Grell,Philippe A. Cassier,Carlos Gomez-Roca,Iphigenie Korakis,David Bechard,L. Palova Jelinkova,Irena Adkins,Sascha Tillmanns,J Kiemle-Kallee,Aurélien Marabelle,Stéphane Champiat +14 more
TL;DR: SOT101 as monotherapy and in combination with pembrolizumab showed a favorable safety profile and highly promising efficacy signals with one ongoing CR and several long-lasting PRs were reported in CPI-naïve and CPI pretreated pts, including CPI-resistant tumors.
10
Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study
Yann Vano,Letuan Phan,Gwenaelle Gravis,Iphigenie Korakis,Friedrike Schlürmann,Denis Maillet,Mostefa Bennamoun,Nadine Houede,Delphine Topart,Delphine Borchiellini,Philippe Barthélémy,Raffaele Ratta,Thomas Ryckewaert,Ali Hasbini,Sophie Hans,Sheik Emambux,Sandra Cournier,E. Braychenko,Reza Elaidi,Stéphane Oudard +19 more
TL;DR: The CABIR study as discussed by the authors showed that cabozantinib may be more effective than nivolumab in the third-line setting, possibly related to an ability of cabozantzinib to overcome resistance to PD-1 blockade.
7
Abstract 2129: Predictive response biomarkers from Phase I clinical trial of a SIRPalpha inhibitor BI765063, stand-alone and in combination with ezabenlimab, a PD1 inhibitor, in patients with advanced solid tumors
Stéphane Champiat,Philippe A. Cassier,Nuria Kotecki,Carlos Gomez-Roca,Iphigenie Korakis,Antoine Italiano,Mabrouk M. Elgadi,Thomas Vandewalle,Isabelle Girault,Nina Salabert-Le Guen,Donogh O'Brien,Nicolas Poirier,Bérangère Vasseur,Dominique Costantini,C. Fromond,Françoise Bono,Jean-Pierre Delord +16 more
TL;DR: In this article , the authors investigated BI765063 predictive response markers from Phase I clinical trial of a SIRPalpha inhibitor in patients with advanced solid tumor patients (pts) showed preliminary efficacy as monotherapy (MONO), and in combination with PD-1 inhibitor ezabenlimab (COMBO).
2